Answers are grounded in this paper and cite their sources.
Rheumatoid arthritis (RA) and its treatments increase the susceptibility to tuberculosis (TB), mainly in TB-endemic settings. Latent TB infection (LTBI) screening is mandatory before biologic disease-modifying antirheumatic drugs. However, data on LTBI among RA patients receiving conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), particularly from north India, are limited. Tuberculin skin testing (TST) may underestimate LTBI in patients with RA because of impaired cell-mediated immunity and reduced delayed-type hypersensitivity responses. In this prospective cross-sectional study, to exclude active TB, 146 consecutive adults with RA (ACR/EULAR 2010 criteria) receiving csDMARDs for ≥3 months underwent Mantoux TST (2 tuberculin units purified protein derivative; reading at 48-72 hours) and chest radiography . Using the conventional cut-off (≥10 mm), LTBI prevalence was 8.2% [12/146; 95% confidence interval (CI) 4.3-13.2%]. Using an immunosuppression-adjusted threshold (≥5 mm), prevalence was 23.3% (34/146; 95% CI 17.8-29.4%). The frequency of 0 mm TST induration was high (76.7%; 112/146). According to univariate analysis, LTBI positivity was linked to higher C-reactive protein (CRP), diabetes, fasting glucose ≥100 mg/dL, current smoking, smoking index >200, and urban residency. In multivariable logistic regression (outcome defined as ≥5 mm), smoking index >200 [adjusted odds ratio (OR) 11.47; 95% CI 1.52-86.6; p=0.018] and higher CRP (adjusted OR 1.036 per mg/L; 95% CI 1.006-1.070; p=0.018) remained independently associated with LTBI. Among RA patients on csDMARDs in a north Indian tertiary center, LTBI prevalence ranged from 8.2% (≥10 mm) to 23.3% (≥5 mm). Application of the ≥5 mm TST threshold substantially increased the estimated LTBI prevalence. The high proportion of participants with 0 mm TST induration suggests reduced TST responsiveness in this population. Further studies incorporating interferon-γ release assays are needed to determine the optimal LTBI screening strategy in patients with rheumatoid arthritis receiving csDMARD therapy.
No takes yet. Share an insight, caveat, or question.
Parmar et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: